Stockwinners Market Radar for July 02, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:04 EDT ARC Document receives non-binding 'go-private' proposal - The Special Committee of the Board of Directors of ARC Document Solution announced that it received a non-binding proposal on April 8, 2024 from the Company's Chairman and Chief Executive Officer, Kumarakulasingam Suriyakumar, outlining Mr. Suriyakumar's intent to explore and evaluate a potential acquisition of all of the outstanding shares of the Company not already owned by Mr. Suriyakumar in a going-private transaction at a purchase price of $3.25 per share in cash. On June 27, 2024, Mr. Suriyakumar, Dilantha Wijesuriya, the Company's President and Chief Operating Officer, Jorge Avalos, the Company's Chief Financial Officer, Rahul Roy, the Company's Chief Technology Officer, Sujeewa Sean Pathiratne, a private investor, and certain entities affiliated with such persons agreed in principle that they will work with each other to negotiate and consummate the Proposed Transaction. In response to the proposal, on April 8, 2024, a special committee of the board of directors of the Company consisting entirely of independent, disinterested directors (the "Special Committee") was formed to review and evaluate the Proposed Transaction. The Special Committee retained William Blair & Company, L.L.C. to provide financial advice and K&L Gates LLP as legal counsel to assist in its ongoing review and evaluation of the Proposed Transaction and the Company's other strategic alternatives. Wilmer Cutler Pickering Hale and Dorr is acting as legal counsel to the Company. The Special Committee intends to carefully consider the Proposed Transaction with the assistance of its independent financial and legal advisors.

20:05 EDT Cathie Wood's ARK Investment bought 505K shares of Recursion Pharmaceuticals

19:50 EDT Medalist Diversified REIT Inc trading halted, news pending

19:50 EDT ASLAN Pharmaceuticals trading halted, news pending

17:45 EDT Denali Capital Acquisition Corp trading resumes

17:25 EDT AdaptHealth announces appointment of Dale Wolf as chairman - AdaptHealt announced the appointment of Dale Wolf as Chair of the Board of Directors, effective July 1. Wolf has served on AdaptHealth's Board since November 2019 and will assume the role from outgoing Chairman Richard Barasch. Additionally, Suzanne Foster, AdaptHealth's Chief Executive Officer, has joined the Board of Directors, effective May 20, .

17:23 EDT Lockheed Martin awarded $226.85M Army contract - Lockheed Martin was awarded a $226.85M hybrid contract for procurement of Army Tactical Missile System guided missile and launching assembly. Bids were solicited via the internet with one received. Work will be performed in Grand Prairie, Texas, with an estimated completion date of December 30, 2028. FY24 Foreign Military Sales funds in the amount of $226.85M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:19 EDT Lockheed Martin awarded $520.4M Air Force contract modification - Lockheed Martin has been awarded a not-to-exceed $520.4M fixed-price incentive modification to a previously awarded contract for Foreign Military Sales Block 70/72 F-16 Viper Shield electronic warfare suite production. The contract modification expands the current long lead materials contract to allow the contractor to begin production tasks. The modification brings the total cumulative face value of the contract to $897.4M. Foreign Military Sales funds in the amount of $177.7M are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:15 EDT Identiv announces stockholder approval of transaction with Vitaprotech - Identiv announced that its stockholders approved the asset sale transaction with Vitaprotech, a security solutions provider, at the Company's Annual Meeting held on June 28, 2024. The Company sought stockholder approval of the asset sale. Approximately 96% of shares voted were voted 'FOR' the asset sale proposal. Approximately 72% of the Company's outstanding shares voted on the proposal, reflecting high interest in and support of the Company's strategic direction, as proposed and recommended by the Company's Board of Directors.

17:05 EDT Everspin Technologies to join Russell 2000 Index - Everspin Technologies announced its inclusion in the Russell 2000 Index as part of the annual reconstitution of the Russell stock indexes. This inclusion was effective at the opening of U.S. equity markets on Monday, July 1, based on the preliminary list of additions posted on Friday, May 24.

17:02 EDT Ideanomics discloses Nasdaq listing deficiency notice - The company states: "Ideanomics announced that onJune 26, 2024,the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC stating that because the Company's Form 10-K for the fiscal year ended December 31, 2023, reported stockholders' equity of less than the required minimum of $2,500,000 in stockholders' equity for continued listing, and as of that day, the Company did not meet the alternatives of market value of listed securities or net income from continuing operations, the Company no longer complied with Listing Rule 5550(b)(1). Accordingly, this matter serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. The Nasdaq Hearings Panel will consider this matter in their decision regarding the Company's continued listing on The Nasdaq Capital Market and the Company must present its views with respect to this additional deficiency to the Panel in writing no later than July 3, 2024. The Company is working diligently to regain compliance and will provide an update once more information is available."

16:51 EDT Minim receives noncompliance notification from Nasdaq - Minim announced that it received a letter from Nasdaq notifying the company that the staff had determined that the company did not meet the terms of the minimum stockholders' equity requirement of at least $2.5M for continued inclusion on Nasdaq pursuant to Nasdaq Listing Rule 5550. The company announced that it appealed the staff determination from Nasdaq, to a panel to delist the company's securities from Nasdaq because of the company's stockholders' equity requirement. The hearing request to the panel will stay the suspension of the company's securities and the filing of the Form 25-NSE pending the panel's decision. In connection with its request for a hearing, the company has also requested that the staff determination be further stayed pending the resolution of the company's appeal.

16:43 EDT FCA reports Q2 sales down 21% vs. last year - FCA US reports total sales of 344,993 vehicles in the Q2, up 4% from the previous quarter. Overall, Q2 total U.S. sales declined 21% year over year while demonstrating strong quarter-over-quarter improvement. "With the moves we made the first half of the year, including working toward a multi-energy strategy consisting of BEV, PHEV and ICE vehicles that meets the demand of our customers, and pricing adjustments across our U.S. brands, including Jeep, Dodge, Chrysler and Ram, we're seeing significant momentum this quarter over the previous quarter of 2024, both in total U.S. sales, which saw an increase of 4% during the period, and in market share," said Matt Thompson, head of U.S. retail sales. "Additionally, beginning today, we are launching a national 'Summer Select Inventory Bonus Cash' incentive campaign, which will provide up to $2,000 cash back across many of our nameplates."

16:34 EDT Lifeward announces Joseph Turk appointed incoming Chairman - Lifeward, previously ReWalk Robotics, announced that Jeff Dykan, current Chairman of the Lifeward Board of Directors, will retire from his role and will not stand for reelection effective at the 2024 Annual Meeting of Shareholders. Joseph Turk, who has served on Lifeward's Board since 2022, has been appointed as the incoming Chairman and will assume the role following the upcoming shareholder meeting. Under Dykan's leadership, Lifeward , previously ReWalk Robotics, has thrived as it grew from an early-stage concept, attracted a management team to lead development, navigated regulatory clearances - including a De Novo approval with the FDA, conducted an IPO, established an exoskeleton coverage policy for U.S. Veterans under the VA, acquired AlterG to grow its portfolio, and most recently, established reimbursement for personal exoskeletons under Medicare. Lifeward is greatly appreciative of Mr. Dykan's guidance and leadership throughout the Company's history of pioneering the exoskeleton and physical rehabilitation industries

16:32 EDT Stantec appoints Vito Culmone as next CFO - Stantec announced that Vito Culmone will join the company in mid-July as its next executive vice president and chief financial officer. He will officially assume the CFO role on September 3. Culmone will succeed Theresa Jang, who previously announced her plan to retire.

16:31 EDT New Fortress Energy announces launch of Klondike Digital Infrastructure - The company states: "New Fortress Energy announces the launch of Klondike Digital Infrastructure, a power and data center development business dedicated to working with hyperscale clients to build and operate data centers. This venture comes in response to a significant need for turnkey digital infrastructure to support the next stage of explosive growth in artificial intelligence. Klondike is revolutionizing the industry by utilizing behind-the-meter, on-site power. This innovative approach addresses all major constraints of digital infrastructure development, providing grid stability, significant transmission capacity, power reliability, energy cost savings, and scalability."

16:18 EDT Atossa Therapeutics appoints Heather Rees as CFO - Atossa Therapeutics announced the appointment of Heather Rees as the company's new CFO. Rees most recently served as Atossa's senior VP of finance and principal accounting officer. Rees brings almost 30-years of accounting, business and financial experience to the CFO role. She has spent the last seven years of her career at Atossa having joined the company as controller in 2017.

16:14 EDT Cipher Mining produced ~176 BTC in June - Cipher Mining released its unaudited production and operations update for June 2024.In June, Cipher delivered another solid month of production and continued to expand operations, with energization of the 30 MW expansions at each of its Bear and Chief data centers. "At Bear we have now received and installed all the new mining rigs, and we expect to finish installing the remainder of the new mining rigs at Chief later this month," said Tyler Page, CEO of Cipher. Bitcoin Production and Operations Updates for June 2024 include: Cipher produced ~176 BTC in June. As part of its regular treasury management process, Cipher sold ~103 BTC in June, ending the month with a balance of ~2,209 BTC.

16:10 EDT NMPA approves Gyre's avatrombopag maleate tablets for TP associated with CLD - Gyre Therapeutics announced that China's National Medical Products Administration or NMPA has approved Gyre Pharmaceuticals' avatrombopag maleate tablets for the treatment of thrombocytopenia or TP associated with chronic liver disease, CLD,,in adult patients undergoing elective diagnostics procedures or therapy. TP is the most common hematologic complication in patients with CLD and can be life-threatening in severe cases. "The approval of avatrombopag maleate tablets by the NMPA represents an important milestone for Gyre as we expand our rare disease product lines and build our presence in developing treatments for patients with CLD," said Han Ying, Ph.D., CEO of Gyre Therapeutics. "We are eager to launch avatrombopag in China and provide a treatment for patients suffering from this devastating disease."

16:08 EDT Inovio appoints Steven Egge as Chief Commercial Officer - Inovio announced the appointment of Steven Egge as Chief Commercial Officer. Egge will lead the company's commercial strategy and operations as it prepares to potentially launch its first DNA medicine product, INO-3107 as a treatment for recurrent respiratory papillomatosis. Egge comes to Inovio from Sumitomo Pharma, where where he was senior VP and General Manager for Women's Health.

16:06 EDT Scansource names Ken Mills as new President - Intelisys, a ScanSource company, and a leading provider of technology services and solutions, announced the appointment of Ken Mills as its new president. In this role, Mills will lead the company's strategic direction with a focus on driving sustainable growth for the company, its partners and suppliers. He most recently served as CEO for Epic iO Technologies, a tech-enabled SaaS company, where he was instrumental in increasing revenue and shareholder value, as well as developing partner-focused platforms to improve productivity and efficiency.

15:52 EDT Sundance settles with Congo, Jefferies sees gain for Burford Capital - Sundance Resources announced yesterday that following a mediated discussion Congo had recently initiated with Sundance, the execution of a binding but confidential and conditional settlement agreement between Sundance, Congo Iron SA and Congo which is meant to settle the ongoing and previously announced dispute between The company added, "If the cash funds are disbursed as agreed in the Conditional Settlement, then the ICC arbitration will end; conversely, if the funds are not received in due course and for the full amount, then the arbitration will continue undisturbed with the hearing now expected to be held in Paris mid-November this year. If successful, the Conditional Settlement is intended to occur by no later than the end September 2024." Jefferies called the settlement "good news" for Burford Capital that would likely lead to a realized gain on its investment. Sundance today provided an update regarding the proceedings between Sundance and the Republic of Cameroon. "As foreshadowed in the Company's update of 26 April 2024, Sundance has now served its Statement of Reply to Cameroon's Statement of Defence. The proceedings against Cameroon are scheduled to be heard by the International Chamber of Commerce in Paris from 27 to 31 January 2025. The Conditional Settlement with Congo announced on 1 July 2024 will not affect the Company's ICC arbitration against Cameroon."

14:36 EDT Volkswagen of America reports Q2 sales up 31% to 100,612 units - Volkswagen of America reports Q2 sales increased 31% year-over-year to 100,612 units. Jetta and Taos sales "underpinned strong YoY growth by increasing 76% and 49% YoY respectively," the company said in a statement. Atlas sales grew by 37% year-over-year and Atlas Cross Sport by 18%.

14:01 EDT Biogen down 2% after Eli Lilly gets FDA approval for Alzheimer's drug - Shares of Biogen (BIIB) are down $5.42, or 2%, to $226.35 in afternoon trading after Eli Lilly (LLY) announced that the Food and Drug Administration approved Kisunla for adults with early symptomatic Alzheimer's disease, or AD, which includes people with mild cognitive impairment as well as people with the mild dementia stage of AD, with confirmed amyloid pathology. "Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed, which can result in lower treatment costs and fewer infusions," Eli Lilly stated. In afternoon trading, Eli Lilly shares are down about 1% to $906.28.

13:40 EDT Eli Lilly says price of each vial of Kisunla $695.65 - Eli Lilly stated: "In the TRAILBLAZER-ALZ 2 trial, people were able to complete treatment and switch to placebo at 6, 12, or 18 months after they achieved one of the study's treatment goals, minimal levels of amyloid plaque consistent with a visually negative amyloid PET scan. In the overall population of people receiving Kisunla, 17% completed treatment at 6 months, 47% at 12 months, and 69% at 18 months based on an assessment of amyloid levels via an amyloid PET scan." In a chart of Kisunla limited-duration treatment examples, the company said the course of therapy cost for 6 months, 12 months and 18 months would be $12,522, $32,000 and $48,696, respectively.

13:31 EDT Annovis Bio Inc trading resumes

13:26 EDT Honda reports June U.S. sales up 1.1% to 112,742 units - American Honda reports sales up 1.1% in June to 112,742 units and year-to-date sales up 9.3% over the first 6 months of 2023. "We are pleased to see our sales momentum continue through the second quarter, with strong demand for both Honda and Acura models despite the software cyberattack impacting auto dealers nationwide. As we begin to ramp up sales of our all-electric Honda Prologue and Acura ZDX, the flexible strategy of offering fuel efficient petrol, hybrid-electric and EV models is helping us meet the needs of our customers," said Lance Woelfer, vice president of Auto Sales at American Honda Motor Co.

13:03 EDT Marsh McLennan Agency acquires AmeriStar Agency, terms not disclosed - Marsh McLennan Agency, a subsidiary of Marsh, today announced the acquisition of AmeriStar Agency, Inc., a Wayzata, Minnesota-based independent agency. Terms of the acquisition were not disclosed. Founded in 1987, AmeriStar provides a range of insurance coverage solutions to high net worth individuals and commercial clients. All AmeriStar employees, including President Matt Schadow, will join Marsh McLennan Agency and continue to operate out of their existing Wayzata office.

12:13 EDT Nissan reports Q2 U.S. sales down 3.1% to 236,721 units - Nissan Group announced total U.S. second quarter, April through June, sales for 2024 of 236,721 units, a decrease of 3.1% versus the prior year. Reference Link

12:01 EDT Mytheresa falls -5.9% - Mytheresa is down -5.9%, or -30c to $4.77.

12:01 EDT Skillsoft falls -10.9% - Skillsoft is down -10.9%, or -$1.46 to $11.99.

12:00 EDT Nuscale Power rises 7.4% - Nuscale Power is up 7.4%, or 81c to $11.74.

11:53 EDT EVI Industries completes acquisition of Laundry Pro of Florida - EVI Industries announced that it completed the previously announced acquisition of Lakeland, Florida based Laundry Pro of Florida. Laundry Pro is the company's 27th acquisition in the commercial laundry distribution and service industry and the eleventh in the Southeast region of the United States.

11:46 EDT Subaru of America reports June sales up 0.1% to 55,228 vehicles - Subaru of America reported 55,228 vehicle sales for June 2024, a 0.1% increase compared with June 2023. SOA also reported year-to-date sales of 322,443, a 6% increase compared with the same period in 2023.

11:37 EDT Toyota Motor North America reports June U.S. sales down 1.2% to 193,120 vehicles - Toyota Motor North America reported U.S. June sales of 193,120 vehicles, down 1.2% on a volume and daily selling rate basis versus June 2023. June electrified vehicle sales totaled 84,781, up 64.5% on a volume basis and DSR basis, representing 43.9% of total monthly sales. TMNA second quarter U.S. sales totaled 621,549 vehicles, up 9.2% on a volume and DSR basis. Second quarter electrified vehicle sales totaled 247,347, up 63.1% on a volume and DSR basis, representing 39.8% of total sales for the period. TMNA first half U.S. sales totaled 1,186,647 vehicles, up 14.3% on a volume basis and up 12.8% on an DSR basis. First half electrified vehicle sales totaled 454,197, up 67.9% on a volume basis and up 65.7% on an DSR basis representing 38.3% of total sales for the period.

11:22 EDT PNC Financial raises common stock dividend 5c to $1.60 per share - The board of directors of PNC Financial declared a quarterly cash dividend on the common stock of $1.60 per share, an increase of 5c per share, or 3%, from the second quarter dividend of $1.55 per share. The dividend will be payable Aug. 5 to shareholders of record at the close of business July 15. "The increase in our dividend reflects our continued financial strength and our board's confidence in our strategy and outlook," said William Demchak, PNC chairman and Chief Executive Officer.

10:55 EDT Pacira slides after FDA posts approval for Exparel generic - Pacira Biosciences shares are sliding this morning after the FDA website showed approval for another company's generic version of Pacira's pain medication Exparel. The copycat version of Exparel, or bupivacaine liposome, was sponsored by Hengrui, with which Pacira is involved in patent litigation. A court decision is expected later this month, Bloomberg quotes a Needham analyst as having stated. In morning trading, Pacira shares have fallen $6.38, or 22%, to $22.08. Reference Link

10:04 EDT Dow Jones, LSEG enter multi-year data, news, analytics partnership - LSEG and Dow Jones announced a new, multi-year data, news, and analytics partnership. Trusted news from Dow Jones's globally renowned newsrooms will be available within LSEG Workspace. Premium subscribers now have access to thousands of news stories, including market scoops, exclusives, unique insights and commentary from The Wall Street Journal, Barron's, Dow Jones Newswires, WSJ Pro, WSJ Opinion, Investor's Business Daily, MarketWatch, Private Equity News and Financial News plus Dow Jones's Chinese, German and Japanese language news, all at no additional cost. Additionally, LSEG will supply Dow Jones's editorial operations with LSEG Workspace and the latest innovations in workflow and productivity tools, supporting a data-driven newsroom. Journalists will have full access to LSEG content sets including Datastream, Fundamentals & Estimates, StarMine models, Pricing and Reference data along with preeminent deals insights from SDC Platinum.

10:01 EDT Chewy falls -6.2% - Chewy is down -6.2%, or -$1.58 to $23.86.

10:00 EDT CS Disco falls -8.9% - CS Disco is down -8.9%, or -52c to $5.32.

10:00 EDT Skeena Resources rises 8.8% - Skeena Resources is up 8.8%, or 45c to $5.58.

09:52 EDT Wheeler Real Estate Investment Trust trading resumes

09:48 EDT Pure Storage falls -7.1% - Pure Storage is down -7.1%, or -$4.66 to $60.85.

09:47 EDT Barnes & Noble Education rises 5.7% - Barnes & Noble Education is up 5.7%, or 35c to $6.47.

09:47 EDT Skeena Resources rises 6.2% - Skeena Resources is up 6.2%, or 32c to $5.45.

09:35 EDT Co-Diagnostics expands vector control customer base to 25 across 15 states - Co-Diagnostics announced that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week. Co-Dx vector control technology includes Vector Smart PCR tests used in environmental surveillance of mosquito pools for mosquito-borne illnesses like West Nile virus, Zika, dengue and chikungunya. Mosquito abatement districts and other vector control customers can use Vector Smart tests as well as other equipment sold and installed by Co-Diagnostics to receive same-day results of mosquito pool testing, allowing for quicker and more efficient prevention of disease transmission to humans and animals.

09:31 EDT Freeport-McMoRan cuts Q2 copper, gold sales view - Freeport announced that its Indonesian subsidiary, PT Freeport Indonesia, substantially completed construction of its new Manyar smelter in Gresik, Indonesia in June and has commenced commissioning operations. FCX expects the smelter will begin producing copper cathodes in the coming months and continues to target full ramp up by the end of 2024 in line with previous expectations. FCX also announced that on July 2 PT-FI received approval from the Indonesian government to export copper concentrates and anode slimes through December when the full ramp-up of the new processing facilities is expected. PT-FI will continue to pay export duties on copper concentrates during the smelter ramp-up period pursuant to Indonesian regulations. PT-FI's prior concentrate and anode slime export licenses expired on May 31 and PT-FI did not export copper concentrates or anode slimes during June. As a result of the delay in obtaining PT-FI's export license, FCX expects a portion of its second-quarter 2024 production will be shipped in future periods. FCX currently expects its consolidated sales for second-quarter 2024 to be approximately 5% below April guidance of 975M pounds of copper and approximately 30% below April guidance of 500,000 ounces of gold. Consolidated unit net cash costs for second-quarter 2024, which were previously estimated at $1.57 per pound of copper, are currently estimated to approximate $1.77 per pound for the quarter, principally reflecting lower by-product credits as a result of the delay in shipments. FCX's consolidated average copper realization for the second quarter is expected to approximate $4.45 per pound. FCX is reviewing its sales guidance in connection with its routine quarterly forecast updates and does not currently expect a material change to its annual 2024 copper volume guidance. As a result of a change in mine sequencing principally to address wet conditions in certain of the Grasberg Block Cave draw points, 2024 gold sales are expected to approximate 1.8M ounces compared with previous estimates approaching 2M ounces. This change is a timing issue and not expected to affect long-range plans.

09:21 EDT Biogen completes acquisition of Human Immunology Biosciences - Biogen has completed the acquisition of Human Immunology Biosciences, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy study and from the completed Phase 2 antibody-mediated rejection study. These data were presented at the European Renal Association Congress and also published in the New England Journal of Medicine. Felzartamab has also demonstrated proof-of-concept in a Phase 2 study in primary membranous nephropathy and there are plans to advance felzartamab to Phase 3 in AMR, IgAN, and PMN. Felzartamab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority and its safety and effectiveness have not been established.

09:18 EDT Rail Vision collaborating with Railway-News.com in rail industry podcast - Rail Vision announced an upcoming collaboration with Railway-News.com, a railway industry news and information portal, for hosting a monthly podcast with industry leaders called "Rail Evolution". The podcast, expected to launch in July, will cover pressing developments in the railway market, discussed by industry experts from across the globe.

09:16 EDT Edible Garden instituted comprehensive training program in New Jersey - Edible Garden has instituted a comprehensive training program in conjunction with Abilities of Northwest Jersey. Established in October 1974, Abilities of Northwest Jersey is a not-for-profit 501(c)(3) agency dedicated to providing comprehensive, community-integrated employment and day services for individuals with disabilities. Abilities offers four on-site day programs, a medical day program, transition and vocational supports, a vocational rehabilitation program, two thrift boutiques, and a screen printing and embroidery location.

09:14 EDT Stellantis invests further $55M in Archer Aviation after flight test milestone - Archer Aviation (ACHR) has received an additional $55M investment from Stellantis (STLA) under the companies' strategic funding agreement following the achievement of its transition flight test milestone last month. This latest investment builds on Stellantis' series of open market purchases of 8.3 million shares of Archer's stock in March. During 2023, Stellantis invested $110M million in Archer through a combination of open market stock purchases and investments under the companies' strategic funding agreement. Archer remains on track to complete construction of its high-volume manufacturing facility in Georgia later this year. This first phase of the build out is a ~350,000 square foot facility on an ~100 acre site designed to support production of up to 650 aircraft annually.

09:13 EDT TKO Group makes strategic investment in EverPass Media - EverPass Media announced it has acquired UPshow, an on-premise entertainment and performance marketing platform. In addition to the acquisition, TKO Group Holdings, parent company of UFC and WWE, has made a strategic investment in EverPass. Mark Shapiro, president and COO of TKO, has joined the board of EverPass, joining representatives from RedBird Capital and 32 Equity. As part of the integration of UPshow into EverPass, businesses will now have the option to stream NFL Sunday Ticket for the first time ever starting with the upcoming 2024 NFL season. EverPass and UPshow are currently partners for Peacock Sports Pass, a sports package offering commercial businesses access to select events from Peacock's live sports content library, including Big Ten football and basketball, Premier League and the NFL's first-ever regular-season game in Brazil.

09:11 EDT Alvotech announces results from confirmatory patient study for AVT03 - Alvotech announced positive topline results from a confirmatory patient study for AVT03, a proposed biosimilar to Prolia and Xgeva. The study met its primary endpoints. The objective of the study is to demonstrate clinical similarity of AVT03 to Prolia in terms of efficacy, safety, immunogenicity, and pharmacokinetics in postmenopausal women with osteoporosis. The results will be used to support additional indications for AVT03 as a proposed biosimilar to Xgeva, based on extrapolation. Prolia is indicated for the treatment of osteoporosis in postmenopausal women and for bone loss in adult men and women at increased risk of fracture. Xgeva, which is the same biologic in a different presentation, is indicated for prevention of skeletal-related events such as pathological fractures in adults with advanced malignancies involving bone. It is also indicated for the treatment of giant cell tumor in bone. The confirmatory patient study, AVT03-GL-C01, is a randomized, double-blind, parallel design, repeat dose, two arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of AVT03 and Prolia in postmenopausal women with osteoporosis. Approximately 532 participants, postmenopausal women 50 years or older diagnosed with osteoporosis, were randomly assigned between the two arms. Each participant receives three doses of either AVT03 or Prolia, at six-month intervals. The study included a re-randomization in the Prolia arm, with participants receiving a third dose of either AVT03 or Prolia. The primary outcome measures were change from baseline in bone mass density and a biomarker for bone resorption. The primary endpoints were measured at 6 and 12 months, but all participants will be followed until an end of study visit after 18 months from the initial dose. The AVT03-GL-P01 study, assessed the PK, safety, and tolerability of AVT03 compared to Prolia in 209 healthy adult participants, and the AVT03-GL-P03 study assessed the PK, safety, and tolerability of AVT03 compared to Xgeva in 208 healthy adult participants. Both studies met their primary endpoints.

09:09 EDT Ageagle Aerial Systems completes training exhibition for Opposition Forces unit - AgEagle Aerial Systemsrecently completed a training exhibition for the Opposition Forces unit at the National Training Center at Fort Irwin, California in the Mojave Desert. Bill Irby, CEO of AgEagle, commented, "The extreme heat of the Mojave Desert presents a very challenging environment for electronic platforms to operate successfully. As expected, our eBee VISION and eBee TAC units performed with no issues over three days and were able to conduct multiple Beyond Visual Line of Sight flights on the standard antenna configuration."

09:06 EDT Hollysys announces completion of regulatory review of merger transaction - Hollysys Automation Technologies announced that it has been informed by Ascendent Capital Partners that a buyer controlled by Ascendent has obtained all the PRC approvals required to be obtained by the buyer to complete the merger transaction with the Company.

09:06 EDT Hyundai Motor reports June sales of 67,631 units, down 2.5% year-over-year - Hyundai Motor America reported total June sales of 67,631 units, a 2.5% decrease compared with June 2023. Hyundai set total sales records in June for Elantra HEV (+1%), Elantra N (+19%), IONIQ 5 (+17%), Santa Fe HEV (+90%), Tucson HEV (+28%) and Palisade (+57%). Hyundai's total hybrid sales were up 39% in June while Green sales represented 26% of retail. "Once again in the face of yet another industry crisis the Hyundai dealers showed their resiliency by closing Q2 with a 2.2% increase in total sales, resulting in a 1.2% increase for the first half of the year," said Randy Parker, CEO, Hyundai Motor America. "Hyundai's strong performance this quarter was driven by demand for IONIQ 5 along with Tucson and Santa Fe HEVs. Our focus remains on delivering a robust product mix and growing market share."

09:04 EDT Tesla reports deliveries of 443,956 units, production of 410,831 units in Q2 - Tesla stated: "In the second quarter, we produced approximately 411,000 vehicles and delivered approximately 444,000 vehicles. We deployed 9.4 GWh of energy storage products in Q2, the highest quarterly deployment yet. Tesla will post its financial results for the second quarter of 2024 after market close on Tuesday, July 23." Reference Link

09:03 EDT Big Lots partners with Make-A-Wish America - Big Lots announces the launch of the first-ever joint point-of-sale campaign with Make-A-Wish America as part of a new national partnership to help grant wishes to children battling critical illnesses. From July 1-31, Big Lots customers can donate at checkout, and to encourage widespread participation, Big Lots will reward every donation with a coupon for $5 off a future purchase of $15 or more.

09:03 EDT Mullen Automotive closes first sale of Mullen Commercial EV in Massachusetts - Mullen Automotive announced the first sale of its Mullen Commercial electric vehicles - EV - in Massachusetts through its new dealer partner, Eco Auto. The initial delivery will go to a Massachusetts-based company offering custom home building, home renovations and maintenance, property management and painting services. Headquartered in Tewksbury, Massachusetts, Eco Auto is a national franchise of automotive dealerships with a core focus of EVs. Earlier this month, the Mullen THREE qualified for a $15K incentive through the State of Massachusetts MOR-EV program. Massachusetts is a CARB-approved state.

09:02 EDT Bion Environmental appoints Turk Stovall, Bob Weerts to board of directors - Bion Environmental Technologies announced the appointments of Turk Stovall and Bob Weerts to its Board of Directors. Bion previously announced that Turk Stovall would be joining Bion's Board, in addition to assuming leadership of the JV between Bion and Stovall Ranching Companies to develop a new-generation cattle feeding facility in Shepherd, Montana. Also appointed to the Board was Bob Weerts, a successful Minnesota business operator and Bion shareholder since 2020.

08:47 EDT VivoPower announces completion of Kenshaw sale - VivoPower International has completed the sale of one of its non-core business units, Kenshaw Electrical, to ARA Group. This follows the announcement on April 29, that a definitive asset sale agreement had been reached with ARA with expected timing for completion of July 1. The divestment is in line with VivoPower's previously announced strategy to focus on reinvesting in its strong growth businesses including Tembo.

08:45 EDT Crown Electrokinetics CTO Tim Koch to transition to CIO - Crown Electrokinetics announced significant changes in its leadership team to bolster its capabilities further and accelerate to product launch. Effective July 8, 2024, Tim Koch, who co-founded Crown Electrokinetics and has served as its Chief Technology Officer since 2015, will transition to the role of Chief Innovation Officer. As the new Chief Innovation Officer, Tim will focus on delivering electrokinetic film to the market and enhancing the company's product portfolio. Robert Vandal will assume the position of Chief Technology Officer starting July 8, 2024. He recently served as the Senior Director of R&D at Guardian Glass. Francois Prouhet is set to join as the Director of Business Development on July 8, 2024. In this role, Prouhet will utilize his experience to develop Crown's go-to-market strategy, establish business partnerships, and provide support for day-to-day execution. He has previously held positions at Guardian Industries and Cars.com

08:43 EDT Aecon Utilities acquire majority interest in Xtreme for base price of $74M - Aecon Group announced that its subsidiary, Aecon Utilities Group has acquired a majority interest in Xtreme Powerline Construction, an electrical distribution utility contractor headquartered in Port Huron, Michigan for a base purchase price of approximately $73 million, with the potential for additional contingent proceeds. The Transaction is being financed through Aecon Utilities' standalone committed revolving credit facility. Xtreme management are committed to supporting Aecon Utilities' expansion in the U.S. and will retain a minority ownership in Xtreme as well as leadership responsibilities in the Xtreme business in partnership with Aecon Utilities' management team. A privately-owned company founded in 2007, Xtreme is a full-service powerline constructor with approximately 300 employees. Xtreme specializes in overhead distribution line repair, maintenance and expansion services throughout the Eastern United States, and provides emergency restoration services for over 20 utility clients across the U.S.

08:41 EDT Camber Energy says patented technology more than doubles CO2-capture rate - Camber Energy shared the most recent announcement from ESG Clean Energy, advising that test results of the recently installed carbon-capture prototype at ESG's facility in Holyoke, MA indicate ESG's patented water removal technology enables at least twice as much carbon to be captured per pound of adsorbent. This is an industry-changing outcome as it will significantly reduce the size and cost of carbon capture systems, making them much easier and economical to implement, according to ESG. Camber's wholly-owned subsidiary has licensed the intellectual property associated with ESG's clean energy & carbon-capture system for exclusive use in Canada and for multiple locations in the U.S. "These results represent another significant milestone in the development and commercialization of our clean energy system. We were confident we would see these numbers, but it is nice to have them validated with data from an operational unit and finally see the proof in our design," said Nick Scuderi, President of ESG Clean Energy, LLC.

08:39 EDT PodcastOne signs multi-year deal with 'Wholeheartedly with Kendall and Galey' - PodcastOne announced the debut of its latest podcast, Wholeheartedly with Kendall and Galey. Hosted by fan favorite top fitness instructor and wellness influencer Kendall Toole and DIY home renovation expert and HBO MAX host Galey Alix, Wholeheartedly is set to debut July 17, 2024 and with weekly episodes dropping on Wednesdays.

08:38 EDT SaverOne 2014 announces order of 50 SaverOne Systems from food manufacturer - SaverOne 2014 announced a new order of 50 SaverOne Systems from the Israeli subsidiary of one of the world's top food manufacturers, for installation in their employee vehicles. This new order follows several successful trial phases and a prior order in November 2022, during which 80 employee vehicles in Israel were equipped with the SaverOne system. Feedback was reported to be very positive, noting a significant reduction in accidents among these vehicles.

08:37 EDT La Rosa Holdings announces over 200 agents onboarded in June - La Rosa Holdings announced a historic achievement: onboarding over 200 agents in the month of June. The Company believes that this milestone is a testament to La Rosa Realty's continued growth, innovative approach, and commitment to excellence in the real estate industry.

08:36 EDT Telomir Pharmaceuticals added to Russell 3000, Russell Microcap Indexes - Telomir Pharmaceuticals announced that the Company has been added as a member of the broad-market Russell 3000 and the Russell Microcap Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

08:34 EDT Vaxcyte appoints John Furey to board of directors - Vaxcyte has appointed John Furey to its Board of Directors. He currently serves as CEO of Imvax, a clinical-stage biotechnology company developing novel immunotherapies for cancer.

08:33 EDT Inozyme's INZ-701 awarded Fast Track designation by FDA - Inozyme announced that the FDA has granted Fast Track designation to INZ-701 for the treatment of ABCC6 Deficiency. ABCC6 Deficiency is a progressively debilitating condition of the vasculature and soft tissue that is estimated to affect approximately 1 in 25,000 to 1 in 50,000 individuals worldwide. In April, the company announced positive topline safety and immunogenicity data from its ongoing Phase 1/2 trial of INZ-701 in adults with ABCC6 Deficiency.

08:32 EDT Kyndryl Holdings appoints Basile as CIO - Kyndryl announced the appointment of a new Chief Information Officer, CIO, and leadership changes in two of its major practices, Applications, Data and AI and Cloud. Kim Basile has been named Kyndryl's new CIO, succeeding Michael Bradshaw, who is assuming leadership of the company's Applications, Data and AI practice. Additionally, Nicolas Sekkaki has been named the Practice Leader for Kyndryl's Cloud practice.

08:29 EDT Ericsson appoints Johansson as Head of MMEA - Ericsson announces the appointment of Patrick Johansson as its new Head of Market Area Middle East & Africa, MMEA, and Senior Vice President. Johansson who is currently Head of Business Control & Operations at Ericsson's Business Area Cloud Software & Services, will replace Fadi Pharaon whose decision to leave Ericsson was announced in May 2024. Johansson will take up his new position on August 1, 2024, and be based in Riyadh, Saudi Arabia.

08:20 EDT Marimed announces approval of adult-use sales at Panacea Wellness Quincy - MariMed received approval of the Massachusetts Cannabis Control Commission to commence adult-use retail sales at its Quincy Panacea Wellness dispensary. Panacea Wellness Quincy is the third MariMed dispensary in Massachusetts that offers adult-use sales, which is the maximum permissible by state law. The other two adult-use dispensaries are in Beverly and Middleboro. The Company commenced adult-use sales in Quincy on July 2, 2024. The dispensary, which has been operating as a medical-only location, offers a curated selection of products from across the Company's award-winning brand portfolio. They include Nature's Heritage flower and concentrates, Betty's Eddies fruit chews, Bubby's Baked soft-baked goods, Vibations hydrating cannabis drink mixes, and the full suite of our InHouse branded products. In addition to the three Panacea Wellness locations, MariMed's branded cannabis products are distributed to over 200 dispensaries in the Massachusetts cannabis market, which, according to the MCCC, generated $1.8 billion in total cannabis sales during 2023. The Company also announced regulatory approval updates that may have a positive impact on our future operational and financial results. These include: Ohio: Receipt of a provisional dual-use license to add recreational sales to our medical dispensary in Tiffin. Upon state final inspection, MariMed expects to commence adult-use sales. Maryland: Receipt of a Certificate of Occupancy and state approval to commence operations in the newly expanded area of our cultivation facility in Hagerstown, Maryland. MariMed will begin growing in the new flower rooms immediately to meet the high demand for its Nature's Heritage flower and other branded products in that state. Also in Maryland, the pre-occupancy inspection of our second Thrive dispensary in the state is expected to occur today. The Company hopes to commence adult-use operations in this dispensary, located in Upper Marlboro, a town in Prince George's County, later this month.

08:17 EDT Gibson Energy appoints Curtis Philippon as president, CEO - Gibson Energy appointed Curtis Philippon as the Company's new President and CEO, effective August 29, 2024. Mr. Philippon brings over 20 years' experience in the North American energy sector in increasingly senior roles, including most recently, as Executive Vice President, Superior Plus and President, Certarus. Once Mr. Philippon assumes the role, he will be meeting with key stakeholders and immersing himself in the Company's strategic priorities, to maintain the commitment to deliver value to shareholders and execute the long-term strategy.

08:16 EDT Lineage Cell Therapeutics added to membership of 2024 Russell 3000 Index - Lineage Cell Therapeutics announced that the company has been added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on July 1, 2024, as part of the 2024 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, 2024, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000(R) Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "We are pleased with Lineage's continued inclusion within the Russell 3000, which can help continue to expand investor awareness, increase institutional ownership, and provide additional liquidity in our stock," stated Brian M. Culley, Lineage CEO, "This recognition of our progress comes during an exciting time, and we believe that a deeper understanding of Lineage's near term and longer term strategic objectives can help increase support for our novel and exciting approach to cell transplant medicine."

08:14 EDT Annovis Bio's buntanetap shows efficacy in Phase 3 Parkinson's study - Annovis Bio announced new data from its Phase III PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor activities and improving cognitive functions in patients with early Parkinson's disease. Key findings from the study include: buntanetap stops cognitive decline in all enrolled patients and improves cognition in patients with mild dementia; all treatment groups maintained baseline levels, indicating a statistically significant effect of the drug in stopping cognitive decline. Buntanetap improves motor and non-motor PD-related functions in patients with a diagnosis of over 3 years. In patients diagnosed with PD for longer than 3 years, buntanetap significantly improved scores vs. placebo and baseline. Buntanetap improves motor and non-motor PD-related functions in patients with Postural Instability and Gait Difficulty. Buntanetap maintained a consistent safety profile across all participants, with no significant differences between early and advanced PD patients confirming our previous AD data.

08:14 EDT Bionano Genomics announces presentation of OGM utility - Bionano Genomics announced its participation in the International Society for Stem Cell Research Annual Meeting 2024 with a broad range of content covering the utility of optical genome mapping for research, development, and manufacturing applications in stem cell therapy. ISSCR's annual meeting brings together industry, medical, and academic professionals to discuss advances in stem cell research and regenerative medicine. The ISSCR conference will be held July 10-13, 2024, in Hamburg, Germany. As part of a sponsored session titled "High-resolution genome integrity assessment in stem cell therapy development with optical genome mapping," three experts will discuss the critical role of OGM in assessing the genome integrity and off-target events in engineered cells, specifically within the context of stem cell research. Presentations will cover OGM's utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profile of next-generation therapy development and manufacturing. Dr. Lucia Gallego Villarejo from Ruhr University Bochum, Dr. Jeanne Loring from Scripps Research Institute, and Dr. Alicia Bertolotti from Bionano will present in Hall G2 on Friday, July 12, 2024, at 12:00 PM CEST. Two scientific posters by Dr. Alex Hastie and Alex Chitsazan from Bionano, covering the use of OGM in cell manufacturing and bioprocessing applications, will be on display during the conference.

08:11 EDT Snail announces participation in Steam Summer Sale event - Snail announced its participation in the Steam Summer Sale event running now until July 11, 2024. This strategic move caters to Snail's objectives to increase sales and expand its global footprint in the gaming community by leveraging the Steam platform. As part of the summer sale, Bellwright, Snail's most recently released early access title, will be on sale with a 10% discount. Snail's flagship survival franchise ARK is also seeing significant discounts on key titles such as ARK Survival Ascended, PixARK, and ARK Park.

08:10 EDT TOYO announces consummation of business combination - TOYO and Blue World Acquisition Corporation (BWAQ) announced the completion of the previously announced business combination between Vietnam Sunergy Cell Company Limited, a wholly-owned subsidiary of TOYO, and Blue World. The listed company following the Business Combination is TOYO Co., Ltd. The ordinary shares of TOYO are expected to commence trading on the Nasdaq on July 2, 2024, under the ticker symbol "TOYO." The warrants of TOYO are expected to commence trading on the OTC Markets. Liang Shi, the Chief Executive Officer of Blue World, shared: "We are very pleased to announce the successful completion of the Business Combination with TOYO, an advanced solar cell manufacturer experiencing rapid growth. We believe TOYO will uphold its commitment to becoming a reliable provider of comprehensive solar solutions globally. The upcoming Nasdaq listing will serve as a catalyst, significantly enhancing TOYO's international reach by strengthening its brand with potential U.S. customers and unlocking broader access to capital."

08:10 EDT Arq added to Russell 3000 Index - Arq announced that the Company has been added to the broad-market Russell 3000 Index and the Russell 2000 Index, effective July 1, 2024.

08:08 EDT Yatra partners with Cipla to offer exclusive domestic travel services - Yatra Online announced that it has secured the travel mandate for Cipla Limited, a leading global pharmaceutical company headquartered in Mumbai. Under this partnership, Yatra will provide tailored, end-to-end travel services to cater to the diverse needs of Cipla's employees. Key among these services is a customized self-booking tool specifically designed for domestic travel bookings, covering air travel, hotel accommodations, and cab services. Speaking on the partnership, Dhruv Shringi, CEO and Director of Yatra Online, Inc. said, "We are delighted to have been chosen as the travel partner for Cipla. This collaboration underscores our commitment to delivering exceptional travel management services tailored to the unique requirements of our clients. We consider this partnership to be a significant milestone for us, marking an exciting opportunity to extend our world-class travel management services to Cipla."

08:08 EDT Nikola wholesale 72 fuel cell trucks for North American customers in Q2 - For Q2 2024,, Nikola Corporation wholesaled 72 Class 8 Nikola hydrogen fuel cell trucks, above the high end of truck sales guidance of 60 units. For the first half of 2024, Nikola wholesaled 112 hydrogen fuel cell trucks. "We have maintained our 2024 momentum with solid wholesale numbers, new customers such as Walmart Canada, and repeat customers like 4GEN and IMC, purchasing vehicles through our dealer network," said Nikola CEO Steve Girsky. "We are firmly on the field and are continuing to secure our first-mover advantage in zero-emissions Class 8 trucks in North America, as well as with our HYLA hydrogen refueling solutions." All Nikola trucks are assembled in Coolidge, Ariz.

08:08 EDT Verses AI promotes James Hendrickson to COO - VERSES AI announces that James Hendrickson has been appointed Chief Operating Officer. Mr. Hendrickson formerly served as President and General Manager VERSES Enterprise.

08:06 EDT American Airlines signs conditional purchase agreement with ZeroAvia - American Airlines has entered into a conditional purchase agreement with clean aviation innovator ZeroAvia for 100 hydrogen-electric engines intended to power regional jet aircraft with zero inflight emissions save for water vapor. In addition, American has increased its investment in ZeroAvia. American made its first investment in ZeroAvia in 2022 and has also now participated in the company's Series C financing round. The engine agreement follows the Memorandum of Understanding the companies announced in 2022. ZeroAvia is developing hydrogen-electric engines for commercial aircraft, which offer the potential for close to zero inflight emissions. The investment and conditional commitment to purchase novel engine technology contributes to American's goal to achieve net-zero greenhouse gas emissions by 2050. ZeroAvia's hydrogen-electric engines use hydrogen in fuel cells to generate electricity, which is then used to power electric motors to turn the aircraft's propellers. The only inflight emission is low-temperature water vapor.

08:06 EDT MSCI appoints Alvise Munari Chief Product Officer - MSCI announced that Alvise Munari, MSCI's current Chief Client Officer, has been appointed Chief Product Officer. Mr. Munari will now be responsible for leading product development and innovation, applying his deep insights into MSCI's global client base. He will continue to drive strong collaboration between MSCI's product teams and the firm's client coverage, marketing, research, technology, and data teams to develop and deliver innovative solutions to meet investors' complex and unique needs for differentiated tools and insights to power their investment strategies. Mr. Munari has transformed the MSCI global client coverage team through a relentless focus on understanding clients' needs and delivering holistic solutions, leading to record growth and client retention across regions, segments, and products. He has 20 years of prior financial industry experience, including in product innovation leadership roles at Goldman Sachs, Merrill Lynch, and Morgan Stanley. Mr. Munari will continue to report to Baer Pettit, President and Chief Operating Officer at MSCI.

08:04 EDT Alaska Airlines launches routes to La Paz, Monterrey from Los Angeles - Alaska Airlines announces an expansion of its international network with two new Mexico destinations starting this winter. The company will soon start flying between Los Angeles and breathtaking La Paz, as the only U.S. carrier serving the coastal Mexican destination. The company will also become the only U.S. airline to offer daily nonstop flights between Los Angeles and the bustling city of Monterrey when we begin service in February.

08:03 EDT Heron Therapeutics announces acceptance of PAS application for ZYNRELE - Heron Therapeutics announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement, PAS, application for ZYNRELE extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024. If approved, the introduction of the VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time from up to three minutes down to between twenty and forty-five seconds. The user-friendly "container-like" design of the VAN may enhance the safe use of ZYNRELEF, increase adoption, and improve the preparation process. If approved, the VAN is expected to be available for use in the fourth quarter of this year.

07:56 EDT Polestar completes staff reductions - Polestar announced that its staff reductions were completed, resulting in 15% fewer positions, in addition to 10% reduction in 2023.

07:44 EDT Moderna receives project award through BARDA's RRPV consortium - Moderna announced a project award of $176 million through the Rapid Response Partnership Vehicle to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The project award will support late-stage development for an mRNA-based vaccine to enable the licensure of a pre-pandemic vaccine against H5 influenza virus. This subtype of influenza virus causes a highly infectious, severe disease in birds called avian influenza and poses a risk for spillover into the human population. The agreement also includes additional options to prepare and accelerate aresponse to future public health threats.

07:41 EDT Probe Gold appoints Marc Duchanne as VP, exploration - Probe Gold announced the appointment of Marc Ducharme as Vice President of Exploration, effective immediately. Marc Ducharme is an exploration geologist with over 35 years of experience in geology, mineral, and mining exploration. He has extensive experience in the Abitibi region of Quebec, as well as experience in Ontario and on international project

07:37 EDT Marimaca Copper announces channel sample results from Mercedes Satellite target - Marimaca Copper announced results from channel sampling completed at the Mercedes target, located approximately 400m-1,000m north of the Marimaca Oxide Deposit. Chip sampling in 2m intervals was completed along new access road development which is currently being constructed in advance of planned exploration drilling in H2 2024. The new sampling results expand the Mercedes area of interest eastward from the original discovery drilling in 2021, now extending approximately 700m x 500m x 100m depth as indicated in the 2021 discovery drilling. Based on the results of this work, the Company will proceed with plans to execute a follow-up drilling program at the expanded Mercedes AOI commencing in the second half of 2024. Results from the Mercedes sampling compare favourably to the original discovery channel sampling completed at the MOD. Mercedes has similar geological characteristics to the MOD and may represent the northern extension of the same IOCG-system. Mercedes, like the MOD, is hosted in Jurassic intrusive stock and dyke-swarm rock types with mineralization controlled by a major NE sheeted structural system and associated fracture networks, cross-cut by a later series of WNW faults and dykes. Geological surface mapping at Mercedes has also confirmed the presence of NNE trending dacitic dykes, which have an important relationship with the highest grades of mineralization at the MOD. Copper mineralization identified at Mercedes is dominated by green oxides, chrysocolla and wad. Previously completed high-resolution MagDrone surveying at Mercedes demonstrates an anomaly similar in dimension and intensity to the MOD magnetic-inversion model, which coincides with the anomalous geochemical background sampling. While not expected to be incorporated into the Company's ongoing Definitive Feasibility Study, the work completed at Mercedes continues to demonstrate opportunity for future oxide mine life extensions at the MOD. Next steps for Mercedes will be considered following the planned 2024 drilling program. Highlights" Samples were taken in 2m intervals across the newly developed road infrastructure: Highlights from the channel sampling results at Mercedes include: 168m @ 0.26% CuT including: 36m at 0.44% CuT within a broader zone of 80m at 0.28% CuT; and 24m at 0.48% CuT within a broader zone of 46m at 0.39% CuT. 122m @ 0.20% CuT including: 32m at 0.36% CuT within a broader zone of 56m at 0.27% CuT; and 24m at 0.25% CuT within a broader zone of 44m at 0.20% CuT. 12m at 0.50% CuT within a broader zone of 34m at 0.24% CuT. Sampling direction is not considered optimal relative to the structural controls of mineralization given sampling was limited to the direction of new road development, which runs predominantly semi-parallel to the NE trending structures. Drilling program will focus on testing directions near-perpendicular to key structures. Results compare favourably to the original discovery channel sampling at the MOD - which intersected 150m at 0.36% CuT

07:34 EDT Bombardier 'remains actively engaged' with Spirit under existing contracts - The company said, "Bombardier (BDRBF) expects its supply contracts to be maintained to the highest standards of quality and performance. The company remains actively engaged with Spirit (SPR) as part of ordinary course of business under existing contracts."

07:33 EDT Marimed closes acquisition of second Maryland dispensary - MariMed announced the closing of its acquisition of the operating assets of Our Community Wellness & Compassionate Care Center in Prince George's County, Maryland on April 5th. Just prior to closing, MariMed paid the state's adult-use conversion fee and subsequently received an adult-use license to sell retail cannabis products from the Maryland Cannabis Administration. The acquired dispensary has been closed since July 1st, 2023. The Company expects to reopen the dispensary and begin adult-use retail sales by the end of the second quarter, upon regulatory approvals. This marks MariMed's second adult-use Thrive Wellness dispensary in Maryland that the company owns and will be located at 9520 Marlboro Pike in Upper Marlboro, Maryland. MariMed also owns and operates a Thrive Wellness dispensary in Annapolis and a cultivation and processing facility in Hagerstown. MariMed plans to continue seeking additional dispensary acquisitions to achieve the maximum of four allowed in the state.

07:32 EDT Division of U.S. DOJ no longer considers Mylan subject of investigation - Viatris announced that the Antitrust Division of the U.S. Department of Justice, DOJ, has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products. This outcome affirms the Company's longstanding position, which it has consistently maintained and asserted, for many years, that Mylan investigated these allegations thoroughly and found no evidence of wrongdoing on the part of Mylan or its employees.

07:17 EDT O-I Glass to invest $150M in Alloa, UK plant in next two years - O-I Glass plans a major transformation of its Alloa, UK manufacturing plant into an even more technologically advanced facility with an expected significant reduction in CO2 emissions. Over the next two years, the company plans to invest approximately $150 million in a series of upgrades to the site. The transformation includes a rebuild of one of its existing furnaces, featuring state-of-the art technology and improved sustainability performance through several planned measures including gas-oxy combustion and increased levels of renewable energy and recycled glass. In addition, O-I has begun to build an all-new furnace featuring the same technological advancements. This furnace will increase long-term flexibility to serve the company's customers, support their growth plans in the Spirits segment, and strengthen their own sustainability efforts. These investments are consistent with O-I's recently updated sustainability roadmap, which is aligned with the company's previously announced capital spending plan, as well as with expected market demand. The company expects both furnaces to come online in 2025 when these measures will gradually and significantly reduce the plant's emissions and provide another building block of the company's strategy to reduce CO2 emissions 25% by 2030. To fuel the gas-oxy furnaces, O-I is partnering with a supplier to establish an oxygen farm adjacent to the Alloa plant. Bringing more new investment into the area, this state-of-the art facility will separate air into oxygen, nitrogen and argon, and is set to also serve the needs of hospitals and other local manufacturing companies.

07:13 EDT Gilat Satellite awarded over $9M for DoD critical connectivity support - Gilat Satellite's wholly owned US-based subsidiary, DataPath received over $9M in orders in support of the US Department of Defense and other agencies worldwide participating in Field Service and Technical Service Programs. DataPath is deploying technical services and field services in Europe, the Middle East, and the United States to support U.S. Defense end users' critical connectivity requirements. These orders include both contract extensions and new contracts from various partners and agencies.

07:12 EDT Laser Photonics announces larger facility, launch of customer training imminent - Laser Photonics announces it is expanding into a new 50,000-square-foot facility in Lake Mary, Florida. The expansion corresponds with LPC's growing presence throughout North America and beyond. The facility will allow LPC to continue increasing its research and development efforts and will better equip the company to streamline quality control and logistics. The added workspace will also house Laser Photonics' growing sales team as it continues to actively seek out new talents in this department..."We are excited about this move as it gives us ample space to expand our operations," said Wayne Tupuola, CEO of Laser Photonics. "Our Maitland facility will continue its normal R&D operations at increased capacity, while the new Lake Mary location will house our growing customer experience, sales and marketing teams, and the new training center. Stay tuned in to our announcements to stay up to date on when facilities are officially opened."

07:10 EDT PyroGenesis provides responses to investor questions - PyroGenesis Canada provided additional information in response to investor questions submitted in advance of or in response to the Company's annual general meeting of June 27, 2024. Mr. P. Peter Pascali, President and CEO of PyroGenesis, provides responses to investor questions posed at the recent annual general: Question 1: What is the status of the 5 tonne order of titanium metal powder, announced in May 2023, that the Company said was expected to be produced and delivered to the American advanced materials company during 2023? This has not shown up in revenue numbers of the Company's earnings releases; did the project get cancelled? Answer 1: As background, the Company announced its first by-the-tonne commercial order of titanium metal powder produced by its NexGen plasma atomization system, on May 30, 2023. The project did not get cancelled and is very much underway. The titanium powder is being delivered on a different schedule than originally anticipated. The powder is being successfully produced and delivered on an ongoing basis. Question 2: What is the status of the Plasma Resource Recovery System project that was mentioned in the Q1 2024 MD&A Outlook as having a potential contract value of $25-$30 million with a "mid term 3-6 months" possibility? Answer 2: For background, the Company stated as part of the Outlook - Business Line Developments in the Q1 2024 MD&A, that it is in early-stage discussions for the sale of a large waste-to-energy system, called a Plasma Resource Recovery System, to transform municipal solid waste into both energy and chemical products. PyroGenesis' PRRS system is designed to process MSW, industrial waste, and hazardous waste, transforming such into commercially valuable products. These products include gaseous fuel for electricity and heat generation, slag, aggregates suitable for construction, and recoverable metals for recycling. The potential value for this contract was originally defined as between $25 - $30 million. Since publication of the Q1 report, this project has evolved and expanded considerably, and is now being negotiated with a total contract value of between $115 - $160 million. Question 3: At a previous AGM, you were given authorization to change the name of the Company. What is the status of that? Answer 3: This change is in the final phase and an announcement should be upcoming.

07:08 EDT CytoSorbents secures $20M credit facility - CytoSorbents Corporation announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. Armentum Partners, LLC served as financial advisor to the Company on the transaction. Proceeds from the facility are intended to provide non-dilutive working capital to support the Company's ongoing global CytoSorb franchise in critical care and cardiac surgery that generated $32.2 million in trailing 12-month sales as of March 31, 2024, planned marketing applications to U.S. Food and Drug Administration and Health Canada for DrugSorb-ATR and initial launch and commercialization preparations if approved, and refinancing of existing Bridge Bank debt. The credit agreement, which has an initial term of three years, provides up to $20 million in total term loan capital including an initial tranche of $15 million, with immediate availability of $10 million and an additional $5 million with the timely acceptance by U.S. FDA of the Company's planned De Novo application for DrugSorb-ATR and certain liquidity requirements. A second tranche of $5 million would be available in the second half of 2025 with FDA marketing clearance for DrugSorb-ATM to help support an anticipated launch of the therapy in the United States.

07:08 EDT Winnebago's Chris-Craft introduces Sportster 25 - Chris-Craft announced its newest innovation, the Sportster 25. The brand's latest design combines a modern flair with classic Chris-Craft styling and is competitively priced, starting at $149,950. The Sportster 25 boasts a spacious interior with abundant seating and includes plenty of storage. On-plane comfort is supported by a new hull design and thoughtful interior ergonomics. The latest in marine technology enhances the on-board experience for passengers with numerous features and options available to meet a range of tastes and lifestyles.

07:07 EDT Siyata Mobile announces strategic investment in Canadian Towers & Fiber Optics - Siyata Mobile announces that it has committed to an investment in Canadian Towers & Fiber Optics, a Canadian based company that develops, constructs and owns telecommunications infrastructure in the flourishing telecommunication market in Mexico. Siyata CEO, Marc Seelenfreund, commented, "Our investment in CT&FO provides us with an entree into Latin America through an established and fast-growing telecommunications partner. Through this partnership, we will have the opportunity to collaborate with a leading cell tower company to develop new business opportunities for our PTT handsets in Central Mexico and across Latin America as CT&FO further expands its business. Latin America represents a massive market opportunity for PTT devices, and we are excited to leverage CT&FO's leading industry position to further advance our sales efforts."

07:06 EDT Blue Owl Capital completes acquisition of Kuvare Asset Management - Blue Owl Capital announced the completion of its acquisition of Kuvare Insurance Services. The transaction was previously announced in April 2024. KAM is a boutique investment management firm with approximately $20 billion of assets under management as of May 31, 2024. KAM is focused on providing asset management services to the insurance industry, including Kuvare UK Holdings. Blue Owl's acquisition of KAM enhances its ability to serve the insurance market at scale and marks the official launch of Blue Owl Insurance Solutions.

07:05 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted five newly-hired employees stock options to purchase an aggregate of 46,850 shares, and restricted stock units covering an aggregate of 19,435 shares, of BioCryst common stock. The options and RSUs were granted as of June 28, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.18 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

07:05 EDT Polestar reports Q2 deliveries of 13,000 cars, up 80% - Polestar reported its preliminary unaudited financial and operational results for the three months ended March 31 and reports its global deliveries for the second quarter of 2024. Polestar delivered approximately 13,000 cars in the second quarter, a growth of 80% compared to the previous quarter. This takes global deliveries for the first six months of the year to 20,200 with USA, Sweden, Norway and Germany delivering momentum.

07:04 EDT Montrose Environmental releases 2023 Sustainability Report Executive Summary - Montrose Environmental Group released its 2023 Sustainability Report Executive Summary highlighting key accomplishments in the Company's sustainability journey and celebrating innovations creating impact across the globe. The Executive Summary celebrates the Company's 2023 accomplishments including: Submitting near-term GHG reduction targets for validation by the Science-Based Target Initiative; Establishing two new Employee Resource Groups; and Expanding the Company's cybersecurity team and completing over 4,700 hours of cybersecurity training across the organization.

07:03 EDT Checkpoint Therapeutics resubmits BLA for cosibelimab in carcinoma - Checkpoint Therapeutics has completed the resubmission of its Biologics License Application - BLA - to the FDA for cosibelimab, its anti-programmed death ligand-1 antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. The BLA resubmission follows Checkpoint recently reaching alignment with the FDA on its BLA resubmission strategy to potentially address all approvability deficiencies outlined in the complete response letter received last December, in which FDA only cited findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturing organization as approvability issues to address in a BLA resubmission. The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.

07:02 EDT Garmin selected as exclusive marine electronics, audio supplier to IBBI - Garmin announced it was selected as the exclusive marine electronics and audio supplier for Independent Boat Builders, IBBI, the industry's largest purchasing cooperative. Beginning model year 2025, this agreement gives IBBI member-owners direct access to Garmin's full line of marine electronics and audio solutions, including JL Audio, Fusion and Clarion Marine, through 2029. Comprised of a 15-owner network of leading boat brands, IBBI members collectively build more than 25% of all boats sold in the U.S.

07:01 EDT Cyngn to proceed with 1-for-100 reverse stock split - Cyngn announced that it will proceed with a 1-for-100 reverse stock split of its outstanding shares of Common Stock following approval by its Board of Directors. This ratio is within the ratio range approved by stockholders at the Company's annual stockholder meeting held on June 25, 2024. The Reverse Stock Split is expected to become effective at 5 p.m., Eastern Time, on July 3, 2024. Cyngn expects the Company's Common Stock will begin trading on a post-split basis at the market open on July 5, 2024, under the symbol "CYN" with the new CUSIP number 23257B 206. The primary objective of the Reverse Stock Split is to increase the per share market price of the Common Stock to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

06:50 EDT Ferguson announces cancellation, replacement of UK listing - As previously announced, to effect a new corporate structure to domicile the Ferguson plc group's ultimate parent company in the United States, Ferguson entered into a merger agreement, dated as of February 29, 2024, by and among the Company, Ferguson Enterprises Inc., a newly incorporated corporation under the laws of Delaware, and Ferguson 2 Limited, a newly formed Jersey incorporated private limited company and direct, wholly owned subsidiary of New TopCo. The Merger Agreement provides for the merger of Merger Sub with and into the Company, with the Company surviving the Merger as a direct, wholly owned subsidiary of New TopCo and Merger Sub ceasing to exist, on the terms and subject to the conditions of the Merger Agreement. At the extraordinary general meeting on May 30, 2024, shareholders of the Company voted to approve the implementation of the Merger with 99.56% of votes cast in favour. Following receipt of such shareholder approval, and subject to the satisfaction of any outstanding conditions precedent listed in the Merger Agreement, it is anticipated that the Merger and the other transactions contemplated by the Merger Agreement will be consummated on August 1, 2024. Subject to the consummation of the Merger and the implementation date of the Proposed Reforms, with effect from 3:00 a.m. Eastern Time / 8:00 a.m. UK Time on the Effective Date, it is currently anticipated that: the Company's listing on the standard segment of the Official List of the Financial Conduct Authority and its admission to trading on the London Stock Exchange plc's Main Market for listed securities will be cancelled; and New TopCo's common stock will be admitted to the standard segment of the Official List and to trading on the LSE. The Company notes the proposed reforms to the Listing Rules as outlined in FCA consultation paper CP23/31. The FCA has confirmed to the Company that: if the Proposed Reforms are implemented in their current form after the Effective Date, New TopCo will be admitted to the standard segment of the Official List on the Effective Date, and upon the subsequent implementation of the Proposed Reforms, New TopCo will be mapped onto to the new "equity shares" segment of the Official List; and if the Proposed Reforms are implemented in their current form on or before the Effective Date, New TopCo will be admitted to the "equity shares" segment of the Official List on the Effective Date. The Company will notify shareholders once it is clear which Official List listing segment it will be admitted to on the Effective Date. In addition, subject to the consummation of the Merger, it is anticipated that on the Effective Date, the Company's ordinary shares will cease trading on the New York Stock Exchange and New TopCo's common stock will commence trading on the NYSE. On completion of the Merger, New TopCo's common stock is expected to trade on the NYSE and the LSE under the symbol "FERG", the same symbol that currently attaches to the Company's ordinary shares.

06:36 EDT Cartesian says first patient dosed in Phase 2 trial of Descartes-08 in SLE - Cartesian Therapeutics announced that the first patient has been dosed in its Phase 2 open-label clinical trial evaluating Descartes-08 in patients with systematic lupus erythematosus. Descartes-08, Cartesian's lead mRNA cell therapy candidate and a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy is an autologous mRNA CAR-T product candidate targeting B-cell maturation antigen. In contrast to conventional DNA-based CAR-T cell therapies, mRNA CAR-T administration is designed not to require preconditioning chemotherapy and is not expected to carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has previously been administered in patients in a Phase 2 clinical trial for the treatment of myasthenia gravis. To date, the safety profile from the MG trial supports outpatient administration with minimal observation. The Phase 2 open-label trial, which is expected to enroll up to 30 adult patients, is designed to evaluate the safety and tolerability of outpatient administration of Descartes-08 without preconditioning chemotherapy for the treatment of patients with moderate or severe SLE refractory to immunosuppressant therapy. Secondary outcome measures will assess overall disease activity.

06:34 EDT Cartesian Therapeutics says Phase 2b trial of Descartes-08 met primary endpoint - Cartesian Therapeutics announced topline results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis. Descartes-08, Cartesian's lead product candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy directed against the B cell maturation antigen. It is designed to be administered as an outpatient treatment without the need for lymphodepleting chemotherapy required to achieve activity with conventional CAR-T cell therapies. Descartes-08 was previously granted Regenerative Medicine Advanced Therapy Designation and Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of MG. In the Phase 2b double-blind, placebo-controlled, crossover trial, a total of 36 heavily pre-treated, highly symptomatic patients with MG were randomized 1:1 to receive either Descartes-08 or placebo administered as six weekly outpatient infusions without preconditioning chemotherapy. At the conclusion of the trial's Month 3 blinded follow-up assessment, patients receiving placebo were eligible to cross over to Descartes-08 treatment. The primary efficacy endpoint assessed the proportion of patients with a reduction of five points or more in the MG Composite score, a 10-item, 60-point weighted instrument composed of selected components of other validated scales to measure MG severity and impact. Whereas a reduction of three points or more is generally regarded as clinically meaningful, the more stringent endpoint of five points was selected based on clinical responses observed in an earlier study with Descartes-08 in MG. Secondary endpoints assessed safety and tolerability and other validated MG severity scales, including Activities of Daily Living, Quantitative MG, and MG Quality of Life Revised Scale. The pre-specified primary efficacy dataset consisted of a modified intent-to-treat population of all subjects enrolled at academic medical centers who received at least one dose of Descartes-08 or placebo and completed at least one post-baseline MGC score follow-up assessment. The safety dataset comprised all subjects who received at least one dose of Descartes-08 or placebo. The trial achieved its primary endpoint with statistical significance in the pre-specified mITT efficacy population, with 71% of patients treated with Descartes-08 observed to have 5-point or greater improvements in MGC score at Month 3 compared to 25% of patients treated with placebo. In addition, the trial also achieved its primary endpoint with statistical significance in the per-protocol population, with 69% of patients treated with Descartes-08 observed to have 5-point or greater improvements in MGC score at Month 3 compared to 33% of patients treated with placebo. Consistent with previously reported results from the Phase 2a open-label portion of the trial, Descartes-08 responders experienced deep improvements across the MG severity scales at Month 3. The improvements seen at Month 3 persisted or further improved in patients evaluated at their Month 4 and Month 6 follow-up visits, as of the June 19, 2024 data cutoff date. Descartes-08 continues to demonstrate a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy. Consistent with findings from the Phase 2a open-label portion of the trial, Descartes-08 was observed to be well tolerated, and adverse events were transient and mostly mild. Notably, there were no cases of cytokine release syndrome, and no cases of immune effector cell-associated neurotoxicity syndrome.

06:31 EDT KalVista reports inducement grants under Nasdaq listing rule - KalVista Pharmaceuticals announced that the compensation committee of KalVista's board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 84,000 shares of KalVista common stock on July 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $11.89 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista's Inducement Equity Incentive Plan and a stock option agreement covering the grant.

06:09 EDT Digihost reports June cash and crypto position up 18% vs. May - Digihost (DGHI) provided unaudited comparative Bitcoin (BTC) production results for June 2024, combined with an operations update. The company held cash, BTC and cash deposits of approximately $7.1M as of June 30, 2024 vs. $6.0M as of May 31, an increase of approximately 18% over the previous month. Miners at the company's facilities produced approximately 45 BTC during June. The company is integrating 11,000 S21 miners into its facilities, translating to approximately 44MW of shared revenues. The deployment of these miners will be completed in phases, with an expected hash rate increase of 1.2 EH/s, to a targeted total of 3.2 EH/s, by the end of Q3 2024. The company spent approximately $0.4M on capital expenditures, mining infrastructure support equipment, and deposits. The company has continued to monetize a portion of its BTC production to fully fund its energy costs. Digihost's consolidated operating capacity across its three sites represents approximately 90MW of available power and is mining at hashrate of 2 EH/s.

06:06 EDT Immuron requests pre-IND meeting for IMM-529 - Immuron has filed a pre-IND application with the United States Food and Drug Administration for IMM-529 The increased incidence of antibiotic resistant 'superbugs' has amplified the use of broad-spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as Clostridioides difficile. Paradoxically, treatment of Clostridioides difficile infection also involves antibiotic use, and the heavy reliance on antibiotics to control C. diff does not allow for the gut flora to regenerate and predisposes the patient to relapsing CDI. C. diff is currently the most common pathogen in healthcare-associated infections and was deemed an urgent threat in the Center for Disease Control and Prevention's report on antibiotic resistance threats in the United States CDI affects over 400,000 people in the US on a yearly basis, contributing to over 30,000 deaths in the US alone annually. This serious health threat has led to an urgent call for the development of new therapeutics to reduce or replace the use of antibiotics to treat bacterial infections. To address this need, Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent CDI. IMM-529 antibodies targeting C. diff may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI. Immuron is collaborating with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin B, the spores and the surface layer proteins of the vegetative cells. This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including Prevention of primary disease; Protection of disease recurrence and Treatment of primary disease. Importantly IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.

06:02 EDT Selina Hospitality launches 'Work Everywhere' Campaign - Selina Hospitality champions the digital nomad lifestyle encouraging locals and travelers to "Work Everywhere". Selina announces the launch of its "Work Everywhere" campaign. Running through the month of July, this initiative aims to spotlight Selina's CoWork spaces, designed to empower remote workers and digital nomads worldwide. We invite both locals and travelers to discover how our unique amenities and stunning locations can transform the way you work

05:15 EDT Northern Trust appointed by Valverde to provide custody, fund administration - Northern Trust announced that it has been appointed by Valverde Investment Partners to provide custody, fund administration, foreign exchange and cash management services for its newly formed Variable Capital Company, or VCC, fund, along with its sub-fund, ASEAN+ Fund, or VAPF. Valverde is a newly established, Singapore-based, independent investment management firm specializing in ASEAN equities. The VCC launch and its sub-fund, Valverde ASEAN+ Fund, or VAPF, represent Valverde's goal of achieving long-term absolute returns, primarily composed of public traded equities within ASEAN companies.